NCT06160778View on ClinicalTrials.gov

Intravenous Ketorolac Vs. Morphine In Children With Acute Abdominal Pain

PHASE3RecruitingINTERVENTIONAL
Enrollment

495

Participants

Timeline

Start Date

May 27, 2024

Primary Completion Date

January 31, 2029

Study Completion Date

December 31, 2029

Conditions
Acute PainAbdomen, AcuteAbdominal PainAppendicitisEmergenciesChild, Only
Interventions
DRUG

Ketorolac Tromethamine

Intravenous ketorolac given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.

DRUG

Morphine Sulfate

Intravenous morphine given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.

DRUG

normal saline

Intravenous normal saline placebo (labelled as morphine) given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.

DRUG

Normal saline

Intravenous normal saline placebo (labelled as ketorolac) given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.

Trial Locations (1)

T3B 6A8

RECRUITING

Alberta Children's Hospital Emergency Department, Calgary

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

University of Calgary

OTHER